• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Earnings Scheduled For November 20, 2023

    11/20/23 7:11:31 AM ET
    $A
    $BLRX
    $BRBR
    $CENT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $A alert in real time by email

    Companies Reporting Before The Bell

    • Greenland Technologies (NASDAQ:GTEC) is projected to report quarterly earnings at $0.05 per share on revenue of $24.26 million.

    • Pyxis Tankers (NASDAQ:PXS) is estimated to report quarterly earnings at $0.19 per share on revenue of $8.25 million.

    • BioLine Rx (NASDAQ:BLRX) is estimated to report earnings for its third quarter.

    • ReNew Energy Glb (NASDAQ:RNW) is likely to report quarterly earnings at $0.10 per share on revenue of $109.71 million.

    • So-Young Intl (NASDAQ:SY) is projected to report quarterly earnings at $0.02 per share on revenue of $55.38 million.

    • Enlight Renewable Energy (NASDAQ:ENLT) is estimated to report quarterly earnings at $0.10 per share on revenue of $65.70 million.

    • Legend Biotech (NASDAQ:LEGN) is projected to report earnings for its third quarter.

    • Zepp Health (NYSE:ZEPP) is projected to report quarterly earnings at $0.03 per share on revenue of $179.52 million.

    • Full Truck Alliance Co (NYSE:YMM) is projected to report earnings for its third quarter.

    • VEON (NASDAQ:VEON) is expected to report earnings for its third quarter.

    • Fanhua (NASDAQ:FANH) is expected to report earnings for its third quarter.

    • Niu Techs (NASDAQ:NIU) is expected to report earnings for its third quarter.

    Companies Reporting After The Bell

    • Techprecision (NASDAQ:TPCS) is expected to report earnings for its second quarter.

    • Xcel Brands (NASDAQ:XELB) is likely to report quarterly loss at $0.16 per share on revenue of $3.40 million.

    • Central Garden & Pet (NASDAQ:CENTA) is expected to report quarterly earnings at $0.07 per share on revenue of $735.32 million.

    • Central Garden & Pet (NASDAQ:CENT) is projected to report quarterly earnings at $0.07 per share on revenue of $735.32 million.

    • Remark Hldgs (NASDAQ:MARK) is estimated to report earnings for its third quarter.

    • Presto Automation (NASDAQ:PRST) is projected to report earnings for its third quarter.

    • Polished.com (AMEX:POL) is likely to report earnings for its third quarter.

    • Upexi (NASDAQ:UPXI) is expected to report quarterly loss at $0.04 per share on revenue of $26.52 million.

    • Enanta Pharma (NASDAQ:ENTA) is expected to report quarterly loss at $2.00 per share on revenue of $20.60 million.

    • Yalla Group (NYSE:YALA) is estimated to report earnings for its third quarter.

    • Symbotic (NASDAQ:SYM) is estimated to report quarterly loss at $0.12 per share on revenue of $305.16 million.

    • FinVolution Gr (NYSE:FINV) is likely to report earnings for its third quarter.

    • Trip.com Group (NASDAQ:TCOM) is estimated to report earnings for its third quarter.

    • Keysight Techs (NYSE:KEYS) is estimated to report quarterly earnings at $1.87 per share on revenue of $1.30 billion.

    • Fidelis Insurance Hldgs (NYSE:FIHL) is projected to report earnings for its third quarter.

    • Zoom Video Comms (NASDAQ:ZM) is projected to report quarterly earnings at $1.08 per share on revenue of $1.12 billion.

    • BellRing Brands (NYSE:BRBR) is likely to report quarterly earnings at $0.39 per share on revenue of $460.52 million.

    • FS Credit Opp (NYSE:FSCO) is expected to report earnings for its third quarter.

    • Agilent Technologies (NYSE:A) is projected to report quarterly earnings at $1.35 per share on revenue of $1.68 billion.

    • Golub Capital BDC (NASDAQ:GBDC) is estimated to report quarterly earnings at $0.47 per share on revenue of $157.82 million.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A
    $BLRX
    $BRBR
    $CENT

    CompanyDatePrice TargetRatingAnalyst
    Legend Biotech Corporation
    $LEGN
    2/12/2026$24.00Buy → Neutral
    Rothschild & Co Redburn
    Zoom Communications Inc.
    $ZM
    2/5/2026$115.00Peer Perform → Outperform
    Wolfe Research
    Legend Biotech Corporation
    $LEGN
    1/22/2026$21.00Buy → Hold
    TD Cowen
    Agilent Technologies Inc.
    $A
    1/20/2026$180.00Buy
    HSBC Securities
    Central Garden & Pet Company
    $CENTA
    1/16/2026$28.00Neutral → Underweight
    Analyst
    Full Truck Alliance Co. Ltd.
    $YMM
    1/12/2026Neutral → Underweight
    Analyst
    Zoom Communications Inc.
    $ZM
    1/12/2026$106.00Neutral → Buy
    Citigroup
    Fidelis Insurance Holdings Limited
    $FIHL
    1/7/2026$21.00Neutral → Underweight
    Analyst
    More analyst ratings

    $A
    $BLRX
    $BRBR
    $CENT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Legend Biotech downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Legend Biotech from Buy to Neutral and set a new price target of $24.00

    2/12/26 7:23:25 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoom Communications upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Zoom Communications from Peer Perform to Outperform and set a new price target of $115.00

    2/5/26 6:52:31 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    Legend Biotech downgraded by TD Cowen with a new price target

    TD Cowen downgraded Legend Biotech from Buy to Hold and set a new price target of $21.00

    1/22/26 8:26:15 AM ET
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $A
    $BLRX
    $BRBR
    $CENT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for APHEXDA issued to BIOLINERX, LTD.

    Submission status for BIOLINERX, LTD.'s drug APHEXDA (ORIG-1) with active ingredient MOTIXAFORTIDE has changed to 'Approval' on 09/08/2023. Application Category: NDA, Application Number: 217159, Application Classification: Type 1 - New Molecular Entity

    9/11/23 2:15:50 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $A
    $BLRX
    $BRBR
    $CENT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dougher Brendan sold $108,485 worth of shares (3,250 units at $33.38) (SEC Form 4)

    4 - CENTRAL GARDEN & PET CO (0000887733) (Issuer)

    2/11/26 4:36:39 PM ET
    $CENTA
    Consumer Specialties
    Consumer Discretionary

    President, Garden Consumer Pro Walker John D. Iii covered exercise/tax liability with 6,437 shares, decreasing direct ownership by 9% to 61,548 units (SEC Form 4)

    4 - CENTRAL GARDEN & PET CO (0000887733) (Issuer)

    2/11/26 4:06:02 PM ET
    $CENTA
    Consumer Specialties
    Consumer Discretionary

    Chief Accounting Officer Machek Howard covered exercise/tax liability with 1,329 shares, decreasing direct ownership by 3% to 45,618 units (SEC Form 4)

    4 - CENTRAL GARDEN & PET CO (0000887733) (Issuer)

    2/10/26 4:19:16 PM ET
    $CENTA
    Consumer Specialties
    Consumer Discretionary

    $A
    $BLRX
    $BRBR
    $CENT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Clark Della bought $18,660 worth of shares (3,000 units at $6.22), increasing direct ownership by 36% to 11,368 units (SEC Form 4)

    4 - FS Credit Opportunities Corp. (0001568194) (Issuer)

    12/31/25 4:01:03 PM ET
    $FSCO
    Trusts Except Educational Religious and Charitable
    Finance

    Chief Executive Officer Marshall Allan bought $90,000 worth of shares (50,000 units at $1.80), increasing direct ownership by 1% to 4,046,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/23/25 7:53:48 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    CEO and Chairman D Loren Robert W bought $94,908 worth of shares (81,466 units at $1.17), increasing direct ownership by 13% to 687,297 units (SEC Form 4)

    4 - XCel Brands, Inc. (0001083220) (Issuer)

    12/19/25 12:42:34 PM ET
    $XELB
    Multi-Sector Companies
    Miscellaneous

    $A
    $BLRX
    $BRBR
    $CENT
    SEC Filings

    View All

    SEC Form S-3 filed by Enanta Pharmaceuticals Inc.

    S-3 - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

    2/11/26 4:43:43 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Enanta Pharmaceuticals Inc.

    10-Q - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

    2/11/26 4:00:44 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Enlight Renewable Energy Ltd.

    SCHEDULE 13G/A - Enlight Renewable Energy Ltd. (0001922641) (Subject)

    2/11/26 7:16:50 AM ET
    $ENLT
    Electric Utilities: Central
    Utilities

    $A
    $BLRX
    $BRBR
    $CENT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enlight Renewable Energy to Host 2026 Virtual Investor Event on Monday, March 9, 2026

    TEL AVIV, Israel, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Enlight Renewable Energy ((TASE: ENLT, NASDAQ:ENLT), a leading global renewable energy developer and an independent power producer, today announced that it will host a virtual Investor Event on Monday, March 9, 2026, beginning at 10:00 a.m. ET. Members of Enlight's senior management, including Adi Leviatan, Chief Executive Officer of Enlight, and Jared McKee, Chief Executive Officer of Clenera, will deliver presentations and participate in discussions focused on Enlight's execution excellence and its growth engines. The presentations will be followed by a Q&A session. The event will commence at 10:00 a.m. ET and conclude at approximatel

    2/12/26 8:00:00 AM ET
    $ENLT
    Electric Utilities: Central
    Utilities

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award

    Award honors leadership in sustainable laboratory practices and circular economy advancement Agilent Technologies Inc. (NYSE:A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent's inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent's trade‑in and buyback program. The annual award honors the global partner that achieves the highest sustainability impact by diverting end‑of‑life laboratory instruments from landfill and contributing to the circular use of scientific equipment. In 2025, Boehringer Ingelheim led all partners in responsible trade‑in activity, ensuri

    2/11/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $BLRX
    $BRBR
    $CENT
    Leadership Updates

    Live Leadership Updates

    View All

    BellRing Brands Announces Leadership Transition Plan

    ST. LOUIS, Feb. 03, 2026 (GLOBE NEWSWIRE) -- BellRing Brands, Inc. (NYSE:BRBR) (the "Company") today announced that its President and Chief Executive Officer Darcy Davenport has decided to retire from the Company, effective upon the earlier of the appointment of a new Chief Executive Officer or September 30, 2026, the end of the Company's fiscal year. Ms. Davenport will continue to serve as President and Chief Executive Officer and as a member of the Board until the effective date of the transition, after which she will serve in an advisory role to ensure a smooth transition of leadership responsibilities and provide strategic support. The Board has commenced a comprehensive external sear

    2/3/26 7:01:00 AM ET
    $BRBR
    Packaged Foods
    Consumer Staples

    Central Garden & Pet Names Apur Patel Chief Legal Officer

    Seasoned global legal executive with more than 30 years of experience across consumer packaged goods, technology, and healthcare to succeed retiring General Counsel & Secretary George Yuhas Central Garden & Pet Company (NASDAQ:CENT) (NASDAQ:CENTA) ("Central"), a leading consumer goods company in the pet and garden industries, today announced the appointment of Apur Patel as Chief Legal Officer, effective January 26, 2026. Mr. Patel succeeds George Yuhas, who will retire from the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126694850/en/Apur Patel joins Central Garden & Pet as Chief Legal Officer, overseeing all l

    1/26/26 4:35:00 PM ET
    $CENT
    $CENTA
    Consumer Specialties
    Consumer Discretionary

    Keysight Technologies Appoints Liz Morali as Head of Investor Relations

    Keysight Technologies, Inc. (NYSE:KEYS) today announced the appointment of Liz Morali as head of Investor Relations. Morali will lead engagement with Keysight's global investor and analyst community and support clear, consistent communication of the company's strategy, performance, and long-term growth opportunities. "Liz brings deep expertise in investor relations, capital markets, and executive communications, along with a strong understanding of the technology and semiconductor landscape," said Neil Dougherty, Chief Financial Officer, Keysight. "She is a seasoned advisor and has a proven ability to build strong relationships with investors while elevating the clarity, discipline, and e

    1/6/26 8:00:00 AM ET
    $KEYS
    Industrial Machinery/Components
    Industrials

    $A
    $BLRX
    $BRBR
    $CENT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ReNew Energy Global plc

    SC 13D/A - ReNew Energy Global plc (0001848763) (Subject)

    12/10/24 7:57:27 PM ET
    $RNW
    Electric Utilities: Central
    Utilities

    Amendment: SEC Form SC 13D/A filed by ReNew Energy Global plc

    SC 13D/A - ReNew Energy Global plc (0001848763) (Subject)

    12/10/24 7:53:40 PM ET
    $RNW
    Electric Utilities: Central
    Utilities

    Amendment: SEC Form SC 13D/A filed by ReNew Energy Global plc

    SC 13D/A - ReNew Energy Global plc (0001848763) (Subject)

    12/10/24 7:32:48 PM ET
    $RNW
    Electric Utilities: Central
    Utilities

    $A
    $BLRX
    $BRBR
    $CENT
    Financials

    Live finance-specific insights

    View All

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Niu Technologies to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

    BEIJING, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Niu Technologies ("NIU" or "the Company") (NASDAQ:NIU), the world's leading provider of smart urban mobility solutions, today announced that it will report its financial results for the fourth quarter and full year 2025 before the U.S. market opens on Monday, March 16, 2026. The corporate presentation and financial spreadsheets will be posted on NIU's investor relations website at: https://ir.niu.com/financial-information/quarterly-results The Company will host an earnings conference call on Monday, March 16, 2026 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time) to discuss the financial and business results. To join via phone, part

    2/10/26 4:00:00 AM ET
    $NIU
    Auto Manufacturing
    Industrials

    Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025

    Conducting Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA), for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV) Introduced New Immunology Program Focused on MRGPRX2 Inhibition; On Track to Select a Development Candidate in 2H 2026 On Track to File an Investigational New Drug Application (IND) in 1Q 2026 and Report Phase 1 Data in 4Q 2026 for EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate On Track to File an IND in 2H 2026 for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate Strong Financial Position of $241.9 Million Supported by Continuing Retained Roya

    2/9/26 4:01:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care